Showing 5261-5270 of 7110 results for "".
- Roflumilast Foam Aligns with Industry Standards for Seborrheic Dermatitis Care: Studyhttps://practicaldermatology.com/news/roflumilast-foam-aligns-industry-standards-sd-care-study/2463119/A recent study published in the Journal of Clinical and Aesthetic Dermatology supports the approved formulation of roflumilast foam, noting that its alignment with beauty industry standards and exclusion of harmful ingredients is important for the confidence of practitioners using the tr
- InnoCare Completes Patient Enrollment in Phase 2 Trial of ICP-488 for the Treatment of Psoriasishttps://practicaldermatology.com/news/innocare-completes-patient-enrollment-phase-2-trial-icp-488-treatment-psoriasis/2463108/InnoCare Pharma announced the completion of patient enrollment for the phase 2 clinical trial of ICP-488, a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor, for the treatment of psoriasis. The multicenter, randomized, double-blind, placebo-controlled phase 2 study aims to evaluate the e
- Johnson & Johnson Acquires Proteologix, Maker of Atopic Dermatitis Candidate, for $850 Millionhttps://practicaldermatology.com/news/johnson-johnson-acquires-proteologix-maker-atopic-dermatitis-candidate-850-million/2463090/Johnson & Johnson has entered into a definitive agreement to acquire biotech company Proteologix for $850 million in cash, with potential for an additional milestone payment. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to ente
- Oral HSP90 Inhibitor Gets Positive Feedback From FDAhttps://practicaldermatology.com/news/oral-hsp90-inhibitor-gets-positive-feedback-fda/2463023/A first-in-class oral drug candidate for the treatment of hidradenitis suppurativa (HS) received positive feedback from a pre-Investigational New Drug meeting with the US Food and Drug Administration (FDA), according to a press release. MC2 Therapeutics, a commercial stage biotech company
- LEO Pharma Announces Topline Results of Phase 3 Trial in China for Plaque Psoriasis Treatment Enstilarhttps://practicaldermatology.com/news/leo-pharma-announces-topline-results-phase-3-trial-china-plaque-psoriasis-treatment-enstilar/2463007/LEO Pharma announced results from the Enstilar phase 3 trial in China in adult patients living with stable plaque psoriasis. The trial is a phase 3, randomised, investigator-blind, active controlled, parallel group, multicenter trial comparing the efficacy and safety of once daily Enstila
- Fish Residues Could Supply Collagenhttps://practicaldermatology.com/news/fish-residues-could-supply-collagen/2462980/Researchers in Norway believe fish residues can supplement current sources of raw materials for collagen and gelatin, according to a Phys.org article. A project called SUPREME, headed by the Norwegian science institute SINTEF Ocean in collaboration with Norwegian university NTNU and the T
- GLODERM Announces CeraVe Access Grant Recipientshttps://practicaldermatology.com/news/gloderm-announces-access-grant-recipients/2462970/Five dermatologists working in low-resource settings around the world have been awarded $20,000 each as part of the International Alliance for Global Health Dermatology (GLODERM) Mentorship Programme, which aims to increase access to dermatological care in under-served communities. The new GLODER
- Trifarotene Plus Skincare Effective Treatment for Acne-Induced Hyperpigmentationhttps://practicaldermatology.com/news/trifarotene-plus-skincare-effective-treatment-acne-induced-hyperpigmentation/2462920/Trifarotene combined with a skincare regimen was effective for the treatment of acne-induced hyperpigmentation (AIH) accompanying acne vulgaris (AV), according to results from a recent phase IV double-blind study. Researc
- LaserAway Aesthetic Dermatology Chain Welcomes Kelly Lohr as New Customer Officerhttps://practicaldermatology.com/news/laseraway-aesthetic-dermatology-chain-welcomes-kelly-lohr-new-customer-officer/2462909/LaserAway, a prominent aesthetic dermatology chain, has welcomed Kelly Lohr as its inaugural Chief Customer Officer, signaling a move into the health and beauty space, according to a press release from the company. With LaserAway's presence in 145 locations and experiencing significant de
- La Roche-Posay Unveils New Serum to Combat Dark Spotshttps://practicaldermatology.com/news/la-roche-posay-unveils-new-serum-combat-dark-spots/2462880/La Roche-Posay has announced the launch of its Mela B3 Dark Spot Serum & Mela B3 UV Daily Moisturizer SPF 30 products. Powered by Melasyl™, the manufacturer said in a news release, L'Oreal's multi-patented ingredient derived from 18 years of research, represents "a breakthrough in pig